<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Document</title>
</head>
<body>
  <h1>第 4 节我行你不行的灭活疫苗
</h1>
  <p>2021 年 5 月 24 日<span class=" fw-cl "><span>，</span></span>港股上市公司中国生物制药公布了 2021 年的一季报<span class=" fw-cl "><span>，</span></span>但市场的焦点却是会计科目里的这一条<span class=" fw-cl "><span>，</span></span><strong>联营及合营公司贡献利润</strong><span class=" fw-cl "><span>。</span></span></p>
<p>因为这一科目对应的<span class=" fw-cl "><span>，</span></span>主要是科兴中维的 15.03% 的股权收益<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>计算器一按<span class=" fw-cl "><span>，</span></span>出大事了<span class=" fw-cl "><span>！</span></span></p>
<p>科兴中维 2021 年一季度实现了近 100 个小目标的净利润<span class=" fw-cl "><span>。</span></span></p>
<p>要知道<span class=" fw-cl "><span>，</span></span>2020 年 A 股净利润最高的三家医药企业分别是英科医疗<span class=" fw-cl "><span>、</span></span>迈瑞医疗<span class=" fw-cl "><span>、</span></span>恒瑞医药<span class=" fw-cl "><span>，</span></span>即使是去年股价涨了 13 倍的<span class="fw-op  "><span>「</span></span>手套茅<span class=" fw-cl "><span>」</span></span>英科医疗<span class=" fw-cl "><span>，</span></span>全年业绩也不过 70 亿<span class=" fw-cl "><span>。</span></span></p>
<p>历史上也从来没有医药企业的单季度净利润能够超过 50 亿<span class=" fw-cl "><span>。</span></span>科兴中维的 2021 年<span class=" fw-cl "><span>，</span></span>注定载入中国医药行业的历史<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>根据科兴中维公布的消息<span class=" fw-cl "><span>，</span></span>第一季度<span class=" fw-cl "><span>，</span></span>科兴中维的新冠疫苗克尔来福累计发货量达 2 亿剂<span class=" fw-cl "><span>，</span></span>全球接种量达 1 亿剂<span class=" fw-cl "><span>。</span></span>而 4 月单月发货约 1 亿剂<span class=" fw-cl "><span>。</span></span></p>
<p>随着科兴新冠疫苗原液车间三期的投产<span class=" fw-cl "><span>，</span></span>科兴的年产能达到 20 亿剂<span class=" fw-cl "><span>。</span></span>这一下计算器要按炸了<span class=" fw-cl "><span>！</span></span>&nbsp;</p>
<p>灭活疫苗到底有多赚钱<span class=" fw-cl "><span>？</span></span>到底有哪些厂商在做灭活疫苗呢<span class=" fw-cl "><span>？</span></span>&nbsp;</p>
<p>科兴中维生产的新冠疫苗走的是灭活路径<span class=" fw-cl "><span>，</span></span>目前国内两针剂型的新冠疫苗都是灭活疫苗<span class=" fw-cl "><span>。</span></span>生产厂家除了科兴中维<span class=" fw-cl "><span>，</span></span>还有国药集团中国生物旗下的北京所<span class=" fw-cl "><span>、</span></span>武汉所和刚获得紧急使用权的康泰生物<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>其中北京所和科兴的疫苗还获得了世界卫生组织的认可<span class=" fw-cl "><span>，</span></span>成为第 6 和第 7 种登上紧急使用清单<span class="fw-op  "><span>（</span></span>EUL<span class=" fw-cl "><span>）</span></span>的新冠疫苗<span class=" fw-cl "><span>。</span></span>而登上了这份清单<span class=" fw-cl "><span>，</span></span>就获得了向 COVAX<span class="fw-op  "><span>（</span></span>新冠肺炎疫苗实施计划<span class=" fw-cl "><span>）</span></span>供应疫苗的资格<span class=" fw-cl "><span>。</span></span></p>
<p>这意味着我国的疫苗企业开始走向世界<span class=" fw-cl "><span>，</span></span>为全球抗疫贡献中国力量<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>但国际上走灭活路径的新冠疫苗并不多<span class=" fw-cl "><span>，</span></span>获批上市的更是只有我国的 4 家企业和印度的 1 家<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>为什么灭活疫苗会成为我国的主流疫苗<span class=" fw-cl "><span>？</span></span>&nbsp;</p>
<p>要想讲明白这个问题<span class=" fw-cl "><span>：</span></span>灭活疫苗是个啥<span class=" fw-cl "><span>？</span></span>我们得细说一下灭活疫苗的生产过程和工作原理<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p><strong>第一步是灭活病毒<span class=" fw-cl "><span>。</span></span></strong></p>
<p>研究人员获取新冠病毒样本<span class=" fw-cl "><span>，</span></span>之后用猴子的肾细胞培养了大量的新冠病毒<span class=" fw-cl "><span>。</span></span>再让新冠病毒泡个剧毒的化学温泉<span class=" fw-cl "><span>。</span></span>这样一来<span class=" fw-cl "><span>，</span></span>新冠病毒就被杀死了<span class=" fw-cl "><span>，</span></span>但它们的蛋白结构还在<span class=" fw-cl "><span>。</span></span>最后<span class=" fw-cl "><span>，</span></span>研究人员将灭活后的病毒与微量的铝佐剂混合起来<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>佐剂这个东西<span class=" fw-cl "><span>，</span></span>打个比方<span class=" fw-cl "><span>，</span></span>就像斗地主时候的<span class="fw-op  "><span>「</span></span>超级加倍<span class=" fw-cl fw--collapsed"><span>」</span></span><span class=" fw-cl "><span>，</span></span>可以极大的增强免疫反应<span class=" fw-cl "><span>。</span></span></p>
<p><strong>第二步是激发免疫响应<span class=" fw-cl "><span>。</span></span></strong></p>
<p>疫苗打进体内后<span class=" fw-cl "><span>，</span></span>一些灭活病毒会被名为抗原提呈细胞的免疫细胞吞噬<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p><strong>第三步是产生抗体<span class=" fw-cl "><span>。</span></span></strong></p>
<p>抗原提呈细胞将新冠病毒降解<span class=" fw-cl "><span>，</span></span>并将病毒的某个片段展示在细胞表面<span class=" fw-cl "><span>，</span></span>让名为辅助 T 细胞的免疫细胞能检测到这个片段<span class=" fw-cl "><span>。</span></span></p>
<p>如果该片段与 T 细胞表面的一种蛋白质结合<span class=" fw-cl "><span>，</span></span>就会将 T 细胞激活<span class=" fw-cl "><span>，</span></span>并帮助招募其他免疫细胞对疫苗产生响应<span class=" fw-cl "><span>。</span></span></p>
<p>另一种名为<strong> B 细胞</strong>的免疫细胞也可能遇到灭活的新冠病毒<span class=" fw-cl "><span>。</span></span>B 细胞与病毒结合后<span class=" fw-cl "><span>，</span></span>可以将部分或全部病毒吞噬到细胞内<span class=" fw-cl "><span>，</span></span>并在细胞表面将冠状病毒的片段呈现出来<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p><strong>第四步是阻断感染<span class=" fw-cl "><span>。</span></span></strong></p>
<p>接种了疫苗后<span class=" fw-cl "><span>，</span></span>免疫系统能对感染活的新冠病毒产生响应<span class=" fw-cl "><span>。</span></span>B 细胞产生抗体<span class=" fw-cl "><span>，</span></span>与入侵的病毒结合<span class=" fw-cl "><span>，</span></span>阻断病毒侵入细胞<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p><strong>第五步是记住病毒<span class=" fw-cl "><span>。</span></span></strong></p>
<p>疫苗对于新冠病毒的保护效果<span class=" fw-cl "><span>，</span></span>目前的数据看可以保证 6-9 个月<span class=" fw-cl "><span>。</span></span>但免疫系统还有另一种名为记忆 B 细胞的特殊细胞<span class=" fw-cl "><span>，</span></span>记忆 B 细胞也许能记住几年<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p><strong>灭活疫苗是一项非常成熟的技术<span class=" fw-cl "><span>，</span></span>它有两大优点<span class=" fw-cl "><span>：</span></span>使用安全<span class=" fw-cl "><span>，</span></span>即使有免疫缺陷<span class=" fw-cl "><span>，</span></span>也可以接种<span class=" fw-cl "><span>；</span></span>易于保存<span class=" fw-cl "><span>，</span></span>可以在 2-8 摄氏度下保存 3 年<span class=" fw-cl "><span>。</span></span>&nbsp;</strong></p>
<p>我国作为最早开始研发新冠疫苗的国家<span class=" fw-cl "><span>，</span></span>为了能够打赢这场和病毒的战争<span class=" fw-cl "><span>，</span></span>采取了<span class="fw-op  "><span>「</span></span>饱和攻击<span class=" fw-cl "><span>」</span></span>的策略<span class=" fw-cl "><span>。</span></span></p>
<p>各家企业采用了各种不同的技术路径研发疫苗<span class=" fw-cl "><span>，</span></span>其中使用灭活路径的比较多<span class=" fw-cl "><span>。</span></span>又因为灭活疫苗的安全性最高<span class=" fw-cl "><span>，</span></span>因此早期获批上市的大都是灭活疫苗<span class=" fw-cl "><span>。</span></span></p>
<p>那为什么灭活疫苗不是欧美研发的重点呢<span class=" fw-cl "><span>？</span></span>&nbsp;</p>
<p>我们上面说过<span class=" fw-cl "><span>，</span></span>灭活疫苗的研发和生产都要用到完整的活病毒<span class=" fw-cl "><span>，</span></span>这就存在着病毒泄露的风险<span class=" fw-cl "><span>，</span></span>因此所有的研发生产活动都必须在生物安全防护三级<span class=" fw-cl "><span>，</span></span>也就是 P3 实验室内进行<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>2020 年<span class=" fw-cl "><span>，</span></span>为了储备足够的灭活疫苗制备产能<span class=" fw-cl "><span>，</span></span>中国电子科技集团旗下的几家公司一直在建设用于疫苗生产的 P3 级别的生产车间<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p><strong>所以灭活疫苗最大的问题在于前期投入大<span class=" fw-cl "><span>，</span></span>产能放大困难<span class=" fw-cl "><span>。</span></span></strong>除了中国和印度<span class=" fw-cl "><span>，</span></span>谁都做不到年产 10 亿剂以上的产能水平<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>那为什么中国的灭活疫苗能够得到 WHO 的认可<span class=" fw-cl "><span>，</span></span>而全球第一大疫苗生产国印度的灭活疫苗却频频出岔子呢<span class=" fw-cl "><span>？</span></span>&nbsp;</p>
<p>这是因为<span class=" fw-cl "><span>，</span></span>中国在传统灭活疫苗的基础上又取得了新的技术突破<span class=" fw-cl "><span>，</span></span>在各个技术环节上都达到了国际领先的水平<span class=" fw-cl "><span>，</span></span>这就是当初我们选择灭活的底气——技术有积累<span class=" fw-cl "><span>，</span></span>产能有保障<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>在 2020 年新冠疫情开始的时候<span class=" fw-cl "><span>，</span></span>谁也没想到疫情会发展成堪比 100 年前西板牙大流感的<span class="fw-op  "><span>「</span></span>超级瘟疫<span class=" fw-cl fw--collapsed"><span>」</span></span><span class=" fw-cl "><span>。</span></span>毕竟新冠的两个哥哥 SARS 和 MERS<span class=" fw-cl "><span>，</span></span>都只闹腾了很短的时间就销声匿迹了<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>欧美的疫苗企业都是私企<span class=" fw-cl "><span>，</span></span>考虑到投入回报比的问题<span class=" fw-cl "><span>，</span></span>自然选择尝试 mRNA 等更有<span class="fw-op  "><span>「</span></span>性价比<span class=" fw-cl "><span>」</span></span>的路线<span class=" fw-cl "><span>。</span></span>而随着新冠疫情的不断蔓延<span class=" fw-cl "><span>，</span></span>现在英法两国也在合作开发灭活新冠疫苗<span class=" fw-cl "><span>，</span></span>2021 年 4 月份刚进入临床二期<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>应该说<span class=" fw-cl "><span>，</span></span>在这场全球性的新冠病毒和疫苗的赛跑中<span class=" fw-cl "><span>，</span></span>研发企业跑赢了第一个回合<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>但因为疫苗分配等各种原因<span class=" fw-cl "><span>，</span></span>在第二个回合当中<span class=" fw-cl "><span>，</span></span>新冠病毒正在用快速的变异缩小差距<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>那灭活疫苗对变异病毒依然有效吗<span class=" fw-cl "><span>？</span></span>&nbsp;</p>
<p>灭活疫苗采用的是完整的病毒<span class=" fw-cl "><span>，</span></span>不是一个靶点<span class=" fw-cl "><span>，</span></span>所以产生的抗体也是针对整个病毒蛋白的<span class=" fw-cl "><span>。</span></span>因此相对于针对特定结构的其他类型疫苗<span class=" fw-cl "><span>，</span></span>灭活疫苗在面对变异病毒的时候会更有<span class="fw-op  "><span>「</span></span>战略纵深<span class=" fw-cl fw--collapsed"><span>」</span></span><span class=" fw-cl "><span>。</span></span>如果灭活疫苗无效的话<span class=" fw-cl "><span>，</span></span>现有的其他新冠疫苗基本上全部都无效<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>举个例子<span class=" fw-cl "><span>，</span></span>虽然科兴疫苗在巴西的临床三期数据刚过 50%<span class=" fw-cl "><span>。</span></span>但在智利<span class="fw-op  "><span>「</span></span>真实世界研究<span class=" fw-cl "><span>」</span></span>的数据显示<span class=" fw-cl "><span>，</span></span>在第二剂科兴疫苗接种 14 天后<span class=" fw-cl "><span>，</span></span>预防有症状感染的有效率为 65.3%<span class=" fw-cl "><span>，</span></span>预防住院治疗的有效率为 87%<span class=" fw-cl "><span>，</span></span>预防进入重症监护病房的有效率为 90.3%<span class=" fw-cl "><span>，</span></span>预防感染所致死亡的有效率为 86%<span class=" fw-cl "><span>，</span></span>依然是战胜病毒的利器<span class=" fw-cl "><span>。</span></span></p>
<p>而对于印度变异株<span class=" fw-cl "><span>，</span></span>初步的研究结果也表明疫苗仍然有效<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>灭活疫苗有什么不足呢<span class=" fw-cl "><span>？</span></span>&nbsp;</p>
<p><strong>灭活疫苗最大的不足是无法产生细胞免疫<span class=" fw-cl "><span>。</span></span></strong>这是因为灭活疫苗中不含有活病毒<span class=" fw-cl "><span>，</span></span>在人体内形成的免疫反应比较弱<span class=" fw-cl "><span>。</span></span>因此灭活疫苗必须要使用佐剂来加强效果<span class=" fw-cl "><span>，</span></span>而且必须要打两针<span class=" fw-cl "><span>。</span></span></p>
<p>第一针是让你身体里的免疫系统认识坏人<span class=" fw-cl "><span>，</span></span>第二针则是让免疫系统认出上次来的坏人并且<span class="fw-op  "><span>「</span></span>痛打<span class=" fw-cl "><span>」</span></span>一顿<span class=" fw-cl "><span>。</span></span>所以如果是接种灭活疫苗<span class=" fw-cl "><span>，</span></span>一定要打满两针后十四天才能获得最好的保护效果<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>正因为必须打满两针<span class=" fw-cl "><span>，</span></span>全国的很多地方在 6 月 10 号-6 月 30 号之间停止接种灭活疫苗第一针<span class=" fw-cl "><span>，</span></span>全力保障第二针的接种<span class=" fw-cl "><span>。</span></span></p>
<p>不过目前<span class=" fw-cl "><span>，</span></span>科兴的年产能已经达到 20 亿剂<span class=" fw-cl "><span>，</span></span>北京所和武汉所的合计年产能也超过了 30 亿剂<span class=" fw-cl "><span>，</span></span>可以为全球的抗疫做出更大的贡献<span class=" fw-cl "><span>。</span></span></p>
<p><strong>灭活疫苗还有一个短板就是中和抗体滴度普遍较低<span class=" fw-cl "><span>。</span></span></strong>只有康泰生物的灭活疫苗在临床 I/II 期试验中表现出色<span class=" fw-cl "><span>，</span></span>但还需要等待临床三期的数据<span class=" fw-cl "><span>。</span></span></p>
<p>康泰生物目前的年设计产能是 2 亿剂<span class=" fw-cl "><span>，</span></span>最大可提升至 6 亿剂<span class=" fw-cl "><span>。</span></span></p>
<p>2021 年 5 月<span class=" fw-cl "><span>，</span></span>康泰的新冠疫苗获得紧急授权上市<span class=" fw-cl "><span>，</span></span>这将极大的提升康泰生物的净利润水平<span class=" fw-cl "><span>。</span></span>即使按照一剂盈利 20 元计算<span class=" fw-cl "><span>，</span></span>也可以增加 20 亿到 40 亿的净利润<span class=" fw-cl "><span>，</span></span>比 2020 年的营收都要高<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>面对此次新冠疫情<span class=" fw-cl "><span>，</span></span>我国的疫苗生产企业证明了自己的能力<span class=" fw-cl "><span>。</span></span>利用新型灭活疫苗的生产技术<span class=" fw-cl "><span>，</span></span>生产了足够全国人民使用的灭活疫苗<span class=" fw-cl "><span>，</span></span>同时也支援了其他国家<span class=" fw-cl "><span>，</span></span>尤其是很多不具备超低温冷链运输技术的发展中国家<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>对于国内的疫苗生产企业来说<span class=" fw-cl "><span>，</span></span>这次疫情是一个历史性的机遇<span class=" fw-cl "><span>。</span></span></p>
<p>一方面<span class=" fw-cl "><span>，</span></span>国产疫苗<span class="fw-op  "><span>「</span></span>走了出去<span class=" fw-cl fw--collapsed"><span>」</span></span><span class=" fw-cl "><span>，</span></span>经历了国际多中心临床试验和 WHO 的认可<span class=" fw-cl "><span>，</span></span>中国疫苗成功出海<span class=" fw-cl "><span>。</span></span></p>
<p>另一方面<span class=" fw-cl "><span>，</span></span>国内群众对于疫苗的认识更为深刻<span class=" fw-cl "><span>，</span></span>接种意愿得到了很大提高<span class=" fw-cl "><span>，</span></span>提升了其他疫苗品种的天花板<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<div class="customizeRender" data-tag="video" data-resource-id="1479483389229633536" data-is-green="false" data-add-head-tail="true" data-cover-url=""></div>
<p><br></p><p><span style="display:block;font-size: 13px;opacity:0.5;transform:translateY(-20px);">备案号:YXX1eY6XOrI6PKaxpFD0Lp</span></p>
</body>
</html>